Jefferies raises Lexicon Pharmaceuticals stock price target to $0.85

Published 06/08/2025, 17:54
Jefferies raises Lexicon Pharmaceuticals stock price target to $0.85

Investing.com - Jefferies raised its price target on Lexicon Pharmaceuticals (NASDAQ:LXRX) stock to $0.85 from $0.70 while maintaining a Hold rating. The stock, currently trading at $1.16, has shown strong momentum with a 42% gain year-to-date, according to InvestingPro data.

The firm noted that Lexicon will meet with the FDA by early Q4 to discuss oral pilavapadin for diabetic peripheral neuropathy (DPN) pain, which represents a potential $1 billion-plus market opportunity.

Lexicon plans to start two pivotal studies for pilavapadin at the end of 2025 or early 2026, with data expected in 2027, according to Jefferies.

The company’s oral sotagliflozin Phase III data in non-obstructive hypertrophic cardiomyopathy and obstructive hypertrophic cardiomyopathy, another potential $1 billion-plus opportunity, remains on track for the first half of 2027.

Jefferies also highlighted that following a deal with Novo Nordisk (NYSE:NVO) for LX9851, Lexicon’s management continues to seek additional non-dilutive capital, potentially through a business development deal for pilavapadin, to strengthen its Q2 cash position of $168 million ($0.46 per share).

In other recent news, Lexicon Pharmaceuticals Inc. reported a surprising financial performance for the second quarter of 2025. The company announced earnings per share of $0.01, defying expectations of a $0.09 per share loss. This unexpected earnings beat was largely attributed to significant licensing revenue from Novo Nordisk. Lexicon’s total revenue reached $28.9 million, substantially surpassing the projected $6.49 million. These recent developments have captured the attention of investors and analysts alike. While the stock’s pre-market movement was notable, the focus remains on the company’s financial results. Analysts are likely to reassess their positions on Lexicon following this earnings announcement. The unexpected results may influence future projections and evaluations by firms covering the company.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.